MedTrace Logo

BeWell24: Smartphone-based Diabetes Prevention in the VA

NCT03202277 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-05-11

No results posted yet for this study

Summary

Type 2 diabetes (T2D) is a national epidemic and current lifestyle programs and medications are not effectively managing the crisis. This project aims to test a novel smartphone-delivered intervention that simultaneously targets multiple health behaviors (i.e., sleep, sedentary behavior, physical activity,dietary intake) within clinical settings at a large Veteran Health Administration regional hospital. If effective, this project has potential for large-scale implementation nationwide through the VA healthcare system and broad applicability for other populations at T2D risk as well as other disorders.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

BeWell24 smartphone app

This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.

BEHAVIORAL

Health education app

This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.

Sponsors & Collaborators

  • Phoenix VA Health Care System

    collaborator FED

  • Arizona State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-17
Primary Completion
2019-12-14
Completion
2019-12-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03202277 on ClinicalTrials.gov